Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Vistagen reports last patient visit in trial of fasedienol nasal spray in SAD

Vistagen (NASDAQ: VTGN) has announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Phase 3 clinical trial evaluating fasedienol nasal...

May 8, 2026

Developments

PharmaJet Tropis Needle-free Injection System selected to deliver 1.4 million polio vaccine doses in Nigeria

Closely held PharmaJet announced that its WHO-prequalified Tropis ID Needle-free Injection System will be used to deliver approximately 1.4 million doses of fractional inactivated polio vaccine (fIPV), in partnership...

May 7, 2026

Executive Moves

Lindsay Hamelin joins Restart’s BoD

Restart Life Sciences (CSE: HEAL; FSE: HN30; OTC Pink: NMLSF) has announced the appointment of capital markets veteran, Lindsay Hamelin, as an independent director on its board of directors (BoD), effective immediately...

May 7, 2026

Developments

Entrada reveals positive topline results from study of ENTR-601-44 in DMD

Entrada Therapeutics (NASDAQ: TRDA) has announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601...

May 7, 2026

Developments

Perimeter’s FDA PMA approved Claire OCT+AI highlighted on the Joe Rogan Experience podcast

Renowned Silicon Valley venture capitalist, entrepreneur, and former Facebook executive, Chamath Palihapitiya, sat down with popular national podcaster, Joe Rogan, yesterday afternoon to talk about various topics...

May 6, 2026

Developments

Aclarion expands use of Nociscan with Weill Cornell Medicine commercial agreement

Aclarion (NASDAQ: ACON, ACONW) has announced the establishment of a second agreement with Weill Cornell Medicine to expand the use of Nociscan in a study titled “Bone Marrow Aspirate Concentrate Injection with...

May 5, 2026

Developments

TriSalus launches trial evaluating pressure-enabled drug delivery in liver tumors

TriSalus Life Sciences (NASDAQ: TLSI) has initiated patient enrollment for its PREDICTT clinical trial designed to evaluate its novel Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic...

May 5, 2026

Executive Moves

Nancy Saitta and Leilani Bradford join Planet 13’s BoD

Planet 13 Holdings (CSE: PLTH; OTCQX: PLNH) has announced the appointments of the Honorable Nancy Saitta and Leilani Bradford as independent directors, filling two newly created seats on its board of directors (BoD)...

May 5, 2026

Developments

JASN publishes analysis highlighting favorable outcomes from Akebia’s Phase 3 study

Akebia Therapeutics (NASDAQ: AKBA) has announced the publication of a post-hoc win statistics analysis of all-cause mortality and hospitalization from its global Phase 3 INNO2VATE program in the peer-reviewed Journal of...

May 4, 2026

Developments

InflaRx reports new data for izicopan in liver microsomes

InflaRx (NASDAQ: IFRX) has announced new preclinical data demonstrating low reactive metabolite formation of izicopan in human liver microsomes. Izicopan is an investigational, orally administered, small molecule...

May 4, 2026

Executive Moves

Eupraxia appoints Dr. Jeymi Tambiah as CMO

Eupraxia Pharmaceuticals (NASDAQ: EPRX; TSX: EPRX) has announced the appointment of Jeymi Tambiah, MB ChB, FRCS, MS, FAPCR, FFPM, as chief medical officer (CMO), and the retirement of the current CMO, Dr. Mark Kowalski...

May 4, 2026

Developments

Can-Fite reports positive data from study of namodenoson in pancreatic cancer

Can-Fite Biopharma (NYSE American: CANF; TASE: CANF) has announced positive clinical data from its Phase 2a study of namodenoson in patients with advanced pancreatic cancer. According to Can-Fite, the data from the...

April 30, 2026

Subscribe